Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | NQO2 | P16083 | 2/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.35 |
| ▸ | ITGAV | P06756 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18349843 | 0.88 | HDAC1 (0.45) | HDAC1HDAC8HDAC6GAASMN1; SMN2 | |
| SCHEMBL6516358 | 0.82 | HDAC1 (0.46) | HDAC1HDAC8HDAC6GAASMN1; SMN2 | |
| SCHEMBL20371134 | 0.79 | GAA (0.45) | HDAC1HDAC8HDAC6GAAALDH1A1 | |
| SCHEMBL18349841 | 0.78 | HDAC1 (0.35) | HDAC1HDAC8HDAC6GAASMN1; SMN2 | |
| SCHEMBL20371106 | 0.78 | ALDH1A1 (0.38) | GAAALDH1A1KMT2A | |
| SCHEMBL14286694 | 0.76 | NPC1 (0.42) | HDAC1HDAC8HDAC6KMT2ANQO2 | |
| SCHEMBL14286735 | 0.74 | NPC1 (0.40) | HDAC1HDAC8HDAC6NQO2MTNR1A | |
| SCHEMBL19709614 | 0.74 | HDAC6 (0.42) | HDAC1HDAC6GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL20371135 | 0.74 | HDAC6 (0.43) | HDAC6GAAALDH1A1KMT2A | |
| SCHEMBL20528865 | 0.73 | MMP2 (0.42) | GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | HDAC1 2062/4885HDAC8 648/4885HDAC6 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.